← Stack Research Tool

Pair page

Cardiogen with Vesugen

Mechanism-tag overlap and published literature for Cardiogen and Vesugen, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.

Mechanism overlap

Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.

CARDIOGEN VESUGEN 1 UNIQUE TAGS 2 UNIQUE TAGS 0 SHARED
Cardiogen unique khavinson-cardiac-bioregulator
Shared none
Vesugen unique khavinson-short-peptide-bioregulatorvascular

Co-administration notes from the literature

Verbatim summary text pulled from each compound's profile data. Researchers studying Cardiogen and Vesugen have published these mechanism-level observations. Not a co-administration recommendation.

Evidence level: mechanistic only

Vesugen is the Khavinson vascular-endothelial bioregulator (KED). Pairing Cardiogen (myocardium) and Vesugen (vessels) is a common community practice within the longevity-focused Khavinson stack — the two compartments most relevant to cardiovascular aging. Neither is a clinically validated cardiovascular therapy.

Evidence level: mechanistic only

Khavinson-framework short peptide targeting cardiac myocytes rather than vascular endothelium. Cardiogen + Vesugen is the Khavinson "cardiac + vascular" combination.

Quick facts

Cardiogen

RouteOral / SubQ / IM
Half-lifeNot listed
FDA statusNot approved
WADANot specifically listed
Full Cardiogen profile →

Vesugen

RouteOral / sublingual / SubQ (research)
Half-lifeMinutes (peptide); gene effects persist weeks
FDA statusNot approved
WADANot specifically named
Full Vesugen profile →

Literature table

Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.

Year Compound Source Finding
2021CardiogenKhavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. DOI: 10.3390/molecules26227053. PMID 34834147systematic review
2006CardiogenGumen AV, Kozinets IA, Shanin SN, Malinin VV, Rybakina EG. Production of lymphocyte-activating factors by mouse macrophages during aging and under the effect of short peptides. Bulletin of Experimental Biology and Medicine. 2006;142(3):360-362. PMID: 17266159. PMID 17266159preclinical, in vivo
2001CardiogenAnisimov VN, Khavinson VKh, Mylnikov SV. Effect of synthetic dipeptide Thymogen (Glu-Trp) on life span and spontaneous tumor incidence in rats. Mech Ageing Dev. 2001;122(1):41-68. PMID: 11110629. (Program methodology reference.) PMID 11110629preclinical, in vivo
2016CardiogenLinkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine. 2016;161(1):175-178. PMID: 27259486. (Sibling tissue-specifi… PMID 27259486preclinical, in vitro
2011CardiogenFedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and the specific interaction of the peptides with deoxyribooligonucleotides and DNA in vitro. Biochemistry (Moscow). 2011;76(11):1210-1219. PM… PMID 22117548preclinical, in vitro
2012CardiogenKhavinson VKh, Solov'ev AIu, Zhilinskii DV. Molecular mechanism of the peptide regulation of gene expression: a review. Advances in Gerontology. 2012;25(3):447-456. PMID: 23289233. PMID 23289233mechanism / discovery
2003CardiogenKhavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PMID: 12937682. (Sibling-peptide methodology reference.) PMID 12937682mechanism / discovery
2020CardiogenKhavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports. 2020;16(1):118-125. PMID: 31813120. DOI: 10.1007/s12015-019-09938-8. PMID 31813120bioregulator literature
2016CardiogenVanyushin BF, Khavinson VKh. Short Biologically Active Peptides as Epigenetic Modulators of Gene Activity. In: Doerfler W, Casadesús J (eds), Epigenetics — A Different Way of Looking at Genetics. Springer, 2016. DOI: 10.1007/978-3-319-27186-6_5.bioregulator literature
2013CardiogenIvanov EI, Khavinson VKh. Peptide bioregulation and cardiovascular pathology. Advances in Gerontology. 2013;3(4):267-273. (Program-level cardiovascular framing.)bioregulator literature
2012CardiogenKhavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine. 2012;153(1):148-151. PMID: 22808513. PMID 22808513bioregulator literature
2010CardiogenAnisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997. PMID 19633997bioregulator literature
2021VesugenKhavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834146. PMID 34834146systematic review
2016VesugenLinkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bull Exp Biol Med. 2016;161(1):175-178. PMID: 27265131. PMID 27265131preclinical, in vitro
2016VesugenKhavinson VKh, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. PMID: 27905024. PMID 27905024mechanism / discovery
2014VesugenKhavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. PMID: 24920421. PMID 24920421mechanism / discovery
2025VesugenWorld Anti-Doping Agency. 2025 WADA Prohibited List. WADA, 2025.regulatory / registry
2022VesugenKhavinson V, Linkova N, Umnov R. Peptide KED: biological activity and mechanisms of action. Int J Mol Sci. 2022;23(2):852. (KED sequence biology review.)bioregulator literature
2013VesugenKhavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Report 1. Adv Gerontol. 2013;3(2):83-93.bioregulator literature
2013VesugenLinkova NS, Kuznik BI, Khavinson VKh. Peptide bioregulators in vascular aging. Advances in Gerontology. 2013;3(4):267-273.bioregulator literature
2012VesugenKuznik BI, Khavinson VKh, Linkova NS. Heat shock proteins, peptide bioregulators, and aging. Adv Gerontol. 2012;25(3):371-380.bioregulator literature
2010VesugenAnisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19609712. PMID 19609712bioregulator literature
2005VesugenKhavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel, 2005.bioregulator literature
2003VesugenKhavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. PMID 14523363bioregulator literature

Related pair pages

More research context

Frequently asked

Have Cardiogen and Vesugen been studied together?

Researchers have published mechanistic-level co-administration discussion of Cardiogen and Vesugen. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.

What mechanisms do Cardiogen and Vesugen share?

Cardiogen and Vesugen do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.

What is the FDA status of Cardiogen and Vesugen?

Cardiogen: Not approved. Vesugen: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.

Where can I find the full research on Cardiogen and Vesugen?

Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cardiogen profile and the Vesugen profile. The Kalios Stack Research Tool hub lists every compound covered.

Last updated: April 2026